Looking forward to outstanding performance from offline pharmacy: Suneeta Reddy, Apollo Hospitals
Synopsis
Yes, by the fourth quarter, we will be EBITDA neutral and I think that we are working towards that. Most of our expenditure has already been incurred and as the revenues pick up, we will be EBITDA neutral.
As you know, we are a company invested in the future, so we have invested into 24/7 and there you will see that we had Rs 145 crores of EBITDA from the backend which is the physical pharmacies and we had a net burden of Rs 217 crores from 24/7, which makes it a PAT negative of Rs 89 crores and I think this is the reason why you are looking at a muted margin, whereas if you look at the different business verticals, healthcare services margin is at 24.4%, pharmacies margin coming is in at 7.5%. So there are very-very strong margins there in the offline business. The online business has also grown significantly. We have seen that we have crossed our target of Rs 1500 crores of GMV. We have moved to Rs 1643 crores of GMV and we are servicing 7 lakh customers online and offline to our pharmacies. So, there is significant volume growth.
Unlock Leadership Excellence with a Range of CXO Courses
Offering College | Course | Website |
---|---|---|
Indian School of Business | ISB Chief Technology Officer | Visit |
Indian School of Business | ISB Chief Digital Officer | Visit |
IIM Lucknow | Chief Executive Officer Programme | Visit |
Yes, by the fourth quarter, we will be EBITDA neutral and I think that we are working towards that. Most of our expenditure has already been incurred and as the revenues pick up, we will be EBITDA neutral.
Can you just walk us through the outlook for Apollo Health and Lifestyle? What kind of numbers are you pencilling in?
If you look at this year in the performance of AHLL, I think the difference is last year was a COVID year and this year as we go forward, what they have really invested in is a core diagnostic business where they have 882 new centres and therefore, there has been a cash run on account of that.
But we expect revenues to grow to Rs 500 crores in the next 24 months coming from the diagnostic business. We also have 500 clinics. So, they have created a huge network that will become a funnel into the AHLL business, plus revenue and profitable vertical by itself.
We are looking at brownfield expansion. In Bangalore, we have 350 beds planned on the land that we already have. In Hyderabad, we are looking at another 150 beds on the land that we have and we will fund it. We have, let me say, cash and bank balances of about Rs 700 crores.
Stocks Recommendations
First, our fulfilment ratio is very-very high and I think it is the trust that the Apollo brand brings to it. We have a large network. Last year, we opened a thousand stores and we will add another 350 stores. Having said that, the EBITDA margin coming from these stores, it has been driven by private label, where the absolute percentage is currently at 12% of total sales where our margin is at 20%. So, we do look forward to an outstanding performance again from the offline pharmacy.
Currently, if you look at, we are at a blended margin of 24.4% and we have already touched 20% in the new hospitals with higher occupancy. Occupancy is currently trending at around 62%. We have a target of 70%. That 8% will flow down absolutely to the EBITDA and therefore margins will significantly increase. We have increased margins by 250 basis points in healthcare services already.